Navigation Links
Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
Date:3/5/2009

rcinoid syndrome is a chronic condition that is the result of metastatic neuroendocrine tumors that usually originate from the gastrointestinal tract. These tumors secrete large amounts of serotonin, which can cause a variety of symptoms including severe diarrhea and abdominal discomfort. LX1032 acts to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin.

LX1032 is being developed in a product development collaboration with Symphony Capital Partners, L.P. and its co-investors.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1032 and the potential therapeutic and commercial potential of LX1032. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expect
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
2. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
3. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma
6. Spectral presents data on the clinical utility of EAA(TM) at 13th Annual Critical Care for Endotoxemia conference in Japan
7. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
8. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
9. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
10. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
11. EntreMed Presents Initial Clinical Results for ENMD-2076
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)...  Sutro Biopharma today announced that it has ... president of alliance and project management. Dr. Vasquez ... of Sutro,s collaborative partnerships and the development of ... antibodies and antibody-based therapeutics targeting immuno-oncology pathways. ... of experience in the biopharmaceutical sector with expertise ...
(Date:8/4/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a specialty ... an emphasis on the treatment of primary and metastatic ... studies in Europe and the ... Delivery System (CHEMOSAT) will be presented at the upcoming ... be held in Marseille, France , ...
(Date:8/4/2015)... , Aug. 4, 2015 BioElectronics ... over-the-counter ActiPatch® Musculoskeletal Pain Therapy medical devices, announced ... of its ActiPatch 7-day trial device has been ... Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More ... survey and submitted an assessment.  ...
Breaking Medicine Technology:Sutro Biopharma Appoints Nicki Vasquez, Ph.D. as VP of Alliance and Project Management 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2
... DIEGO, Oct. 7 The West Wireless Health ... to Alan Viars, of Videntity, at the Health ... and open source platforms to enable people to ... networks as they work towards achieving health and ...
... 7 VentiRx Pharmaceuticals, Inc., a biopharmaceutical company ... 8 (TLR8) candidates for the treatment of cancer, ... its randomized, placebo controlled clinical trial evaluating VTX-1463 ... demonstrated that VTX-1463 significantly improved allergy symptoms based ...
Cached Medicine Technology:West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0 2West Wireless Health Institute Awards $10K Developer Challenge at Health 2.0 3VentiRx Pharmaceuticals Reports Positive Clinical Data for VTX-1463 in Allergic Rhinitis 2
(Date:8/4/2015)... ... August 04, 2015 , ... School is almost back in session. Parents and ... for the back-to-school scramble. Dublin, OH family dentist , Dr. Cheung (of BrightSmile ... annual dental checkup. In fact, the dentist recently updated the practice’s surgical suite to ...
(Date:8/4/2015)... ... ... Many men are confused about the safety of testosterone replacement therapy. In ... voice of authority for men seeking accurate information about testosterone. , Renew Man™ ... in the safe and effective treatment of low testosterone. In recent years, the experts ...
(Date:8/4/2015)... ... August 04, 2015 , ... Buckeye Health Plan is reminding ... immunizations are covered for members under the Healthchek program . , “Many ... with their immunizations may not be allowed to attend when school begins in ...
(Date:8/4/2015)... ... August 04, 2015 , ... SanusEO, ... Bruce McCalley joins its executive leadership team as Senior Vice President of Sales ... technology companies and expanding global markets with a special emphasis on the healthcare ...
(Date:8/4/2015)... ... August 04, 2015 , ... T.E.N., an information technology ... participating in The ISE® Lions’ Den and Jungle Lounge 2015, which will be held ... Vegas. , During the event, eight emerging security vendors, known as “Gazelles,” will go ...
Breaking Medicine News(10 mins):Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 2Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 4Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 4
... release is available in Spanish . U.S. ... laboratory rats fed blueberries or other foods of interest may ... has paved the way to follow-up experiments, Rosalia C. M. ... Rock, Ark., has determined that several indicators of rat mammary ...
... more common disease striking overweight, younger women is the ... where an osteopathic physician is testing the effectiveness of ... Idiopathic intracranial hypertension, known as IIH or pseudo-tumor cerebri, ... the brain, specifically in the absence of a tumor. ...
... year, 10,000 pregnant women and up to 200,000 newborn babies ... globe have for years been looking in vain for a ... have found the biochemically weakness of the lethal malaria parasite, ... related malaria. The malaria parasite travels via the spit ...
... with colon cancer that had spread to distant sites found ... drug regimen that was not recommended. Those patients were exposed ... for the drugsof more than $2 million. The study, ... the American Society for Clinical Oncology,s annual meeting in Chicago, ...
... Blocking two tiny molecules of RNA a chemical ... of blood vessels that occurs in degenerative eye disorders, UT ... in the Proceedings of the National Academy of Sciences ... (AMD), a vascular eye disorder that affects nearly 2 million ...
... (HealthDay News) -- One of the first and largest national ... that those who identify as gay, lesbian or bisexual are ... The study was conducted by the U.S. Centers for ... 2001-2009. It found that rates of smoking, drinking or other ...
Cached Medicine News:Health News:Mammary gland development of blueberry-fed lab animals studied 2Health News:Researcher tests drug's impact on neurological disease affecting women 2Health News:Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed 2Health News:Many patients with advanced cancers get treatments that won't help 2Health News:Many patients with advanced cancers get treatments that won't help 3Health News:Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders 2Health News:More Risky Behaviors Among Gay, Bisexual High School Students: CDC 2
... the only dura material versatile enough for ... closure, and in cases where biological fixation ... in cases requiring an immediate watertight seal ... biological fixation and sealing are key factors ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Bipolar foot activated forceps....
Medicine Products: